Intellipharmaceutics International Inc. (IPCI)

[nccmtt]

Endo Reports Fourth-Quarter And Full-Year 2016 Financial Results

Nothing about Focalin XR but:

"Revenues of $882 million, a 45 percent increase compared to fourth-quarter 2015; this increase was primarily attributable to the launches of quetiapine extended-release tablets, the generic version of SEROQUEL XR®, and ezetimibe tablets, the generic equivalent of ZETIA®. Par has first-to-file status and associated marketing exclusivity for each product. The introduction of ezetimibe tablets represented the largest product launch in Par Pharmaceutical's history."


http://www.newschannel10.com/story/34621636/endo-reports-fourth-quarter-and-full-year-2016-financial-results

Matteo